Management von Nebenwirkungen unter Immuncheckpointinhibition

Sie gehören zu den bedeutendsten Entwicklungen im Bereich der Onkologie in den vergangenen Jahren: Immuncheckpointinhibitoren (ICI). Die Erstzulassung des ICI Ipilimumab in den USA galt 2011 als eine Revolution in der Onkologie, heute sind ICI aus dem klinischen Alltag der Onkologie nicht mehr wegzudenken. Durch den vermehrten Einsatz steigt auch die Rate an ICI-vermittelten Nebenwirkungen. Der Beitrag skizziert einen Überblick über das Management ICI-vermittelter Nebenwirkungen.

Schlüsselwörter

Immuncheckpointinhibitoren - Gynäko-Onkologie - Immuntherapie - immunvermittelte Nebenwirkungen

• Literatur

• 1 Grywalska E, Sobstyl M, Putowski L. et al. Current Possibilities of gynecologic cancer treatment with the use of immune checkpoint inhibitors. Int J Mol Sci 2019; 20: 4705
• 2 Food and Drug Administration – FDA. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Accessed November 10, 2022 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
• 3 Europäische Arzneimittel-Agentur – EMA. Fachinformation Dostarlimab. Accessed November 10, 2022 at: https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_de.pdf
• 4 Naumann RW, Hollebecque A, Meyer T. et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 Trial. J Clin Oncol 2019; 37: 2825-2834
• 5 Europäische Arzneimittel-Agentur – EMA. Fachinformation Nivolumab. Accessed November 10, 2022 at: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_de.pdf
• 6 Europäische Arzneimittel-Agentur – EMA. Fachinforamtion KEYTRUDA. Accessed November 10, 2022 at: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_de.pdf
• 7 Bartsch R. ESMO 2020: highlights in breast cancer. Memo 2021; 14: 184-187
• 8 Europäische Arzneimittel-Agentur – EMA. Fachinformation Atezolizumab. Accessed November 10, 2022 at: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_de.pdf
• 9 Emens LA, Adams S, Barrios CH. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 2021; 32: 983-993
• 10 IQWIG. Dossierbewertung Auftrag: Version: Stand: A21–145 1.0 11.02.2022 IQWiG-Berichte – Nr. 1289 Pembrolizumab (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V. Accessed November 10, 2022 at: https://www.g-ba.de/downloads/92–975–5227/2021–11–15_Nutzenbewertung-IQWiG_Pembrolizumab-D-752.pdf
• 11 Europäische Arzneimittel-Agentur – EMA. Keytruda pembrolizumab. Accessed November 10, 2022 at: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/keytruda-8
• 12 Arbeitsgemeinschaft Gynäkologische Onkologie – AGO. Empfehlungen gynäkologische Onkologie Kommission Mamma. Accessed November 10, 2022 at: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
• 13 Tewari KS, Monk BJ, Vergote I. et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022; 386: 544-555
• 14 Haanen JBAG, Carbonnel F, Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv119-iv142
• 15 Heinzerling L, de Toni EN, Schett G. et al. Checkpoint Inhibitors. Dtsch Arztebl Int 2019; 116: 119-126
• 16 Heinrich K, von Bergwelt-Baildon M, Theurich S. Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien. Dtsch Med Wochenschr 2021; 146: 1119-1128
• 17 Services Usdohah. Common terminology criteria for adverse events (CTCAE). Version 5.0. 2017. Accessed November 10, 2022 at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
• 18 Champiat S, Lambotte O, Barreau E. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-574
• 19 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345-1356
• 20 Kelly K, Manitz J, Patel MR. et al. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer 2020; 8
• 21 Owen CN, Bai X, Quah T. et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 2021; 32: 917-925
• 22 Johnson DB, Reynolds KL, Sullivan RJ. et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol 2020; 21: e398-e404
• 23 Gunturu KS, Pham TT, Shambhu S. et al. Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients. Support Care Cancer 2022; 30: 4019-4026
• 24 Sonpavde GP, Grivas P, Lin Y. et al. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol 2021; 17: 2545-2558
• 25 Postow MA, Hellmann MD. Adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 1165
• 26 Menzies AM, Johnson DB, Ramanujam S. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28: 368-376
• 27 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768
• 28 Thompson JA, Schneider BJ, Brahmer J. et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 2019; 17: 255-289
• 29 Santini FC, Rizvi H, Plodkowski AJ. et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 2018; 6: 1093-1099
• 30 Loibl S, Schneeweiss A, Huober JB. et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 2021; 39: 506-506
• 31 German Breast Group (GGB). Studien der German Breast Group. Studienübersicht 2022. Accessed November 10, 2022 at: https://www.gbg.de/de/studien/
• 32 AGO, NOGGO. Studien und Umfragen 2022 AGO und NOGGO. Accessed January 11, 2022 at: https://ago-ovar.de/wp-content/uploads/2022/02/2022-01_Studienu%CC%88bersicht-AGO-und-NOGGO.pdf
• 33 Dart SJ, Cook AM, Millward MJ. et al. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Sci Rep 2021; 11: 15312
• 34 Arbeitsgemeinschaft Gynäkologische Onkologie – AGO. Kommission Mamma: Leitlinie „Supportive Therapie“. Accessed November 10, 2022 at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2022/Einzeldateien_Literatur/AGO_2022D_14_Supportive_Therapie_und_NW-Management_REF.pdf